These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38071)

  • 1. Re-evaluation of the antimineralocorticoid effect of the spironolactone metabolite, canrenone, from plasma concentrations determined by a new high-pressure liquid-chromatographic method.
    Dahlöf CG; Lundborg P; Persson BA; Regårdh CG
    Drug Metab Dispos; 1979; 7(2):103-7. PubMed ID: 38071
    [No Abstract]   [Full Text] [Related]  

  • 2. Spirolactones: clinical and pharmacologic studies.
    Corvol P; Claire M; Rafestin-Oblin ME; Michaud A; Roth-Meyer C; Menard J
    Adv Nephrol Necker Hosp; 1977; 7():199-215. PubMed ID: 208407
    [No Abstract]   [Full Text] [Related]  

  • 3. Spironolactone and potassium canrenoate in normal man.
    Ramsay L; Shelton J; Harrison I; Tidd M; Asbury M
    Clin Pharmacol Ther; 1976 Aug; 20(2):167-77. PubMed ID: 780038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.
    Dasgupta A; Tso G; Wells A
    Ther Drug Monit; 2008 Dec; 30(6):744-7. PubMed ID: 18824952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spironolactone and canrenoate-K: relative potency at steady state.
    Ramsay L; Asbury M; Shelton J; Harrison I
    Clin Pharmacol Ther; 1977 May; 21(5):602-9. PubMed ID: 858213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progestogens with antimineralocorticoid activity.
    Losert W; Casals-Stenzel J; Buse M
    Arzneimittelforschung; 1985; 35(2):459-71. PubMed ID: 4039568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone.
    DeFrance A; Armbruster D; Petty D; Cooper KC; Dasgupta A
    Ther Drug Monit; 2011 Feb; 33(1):128-31. PubMed ID: 21079546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canrenone--the principal active metabolite of spironolactone?
    Ramsay LE; Shelton JR; Wilkinson D; Tidd MJ
    Br J Clin Pharmacol; 1976 Aug; 3(4):607-12. PubMed ID: 22216502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canrenone as a partial agonist at the digitalis receptor site of sodium-potassium-activated adenosine triphosphatase.
    Finotti P; Palatini P
    J Pharmacol Exp Ther; 1981 Jun; 217(3):784-90. PubMed ID: 6262496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proceedings: Acute and chronic effects of the aldosterone antagonist spironolactone and its main metabolite canrenone on plasma aldosterone concentration, plasma renin activity, serum electrolytes and on the excretion of aldosterone, fluid and electrolytes in rats.
    Erbler HC; Hilfenhaus M
    Naunyn Schmiedebergs Arch Pharmacol; 1975; 287 Suppl():R52. PubMed ID: 1143449
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of spironolactone on diuresis and urine sodium and potassium excretion in healthy dogs.
    Jeunesse E; Woehrle F; Schneider M; Lefebvre HP
    J Vet Cardiol; 2007 Nov; 9(2):63-8. PubMed ID: 18024236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldosterone antagonism studies in the rhesus monkey.
    Hofmann LM; Pedrera HA; Suleymamov OD
    J Pharmacol Exp Ther; 1977 Jul; 202(1):216-20. PubMed ID: 406381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Membrane activity of canrenone in the normotensive subject: evaluation and significance].
    Ollivier JP; Delamourd L; Leglise D
    Sem Hop; 1981 Mar 8-15; 57(9-10):495-8. PubMed ID: 6261395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone].
    Vergin H; Nuss U; Strobel K
    Arzneimittelforschung; 1986 Mar; 36(3):490-5. PubMed ID: 3707669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of spironolactone and its main metabolite canrenone on the renin-angiotensin-aldosterone-system during long-term treatment in rats.
    Erbler HC
    Acta Endocrinol (Copenh); 1979 Jan; 90(1):147-56. PubMed ID: 760354
    [No Abstract]   [Full Text] [Related]  

  • 16. Antagonism of fludrocortisone by spironolactone and canrenone.
    Huston GJ; Turner P
    Br J Clin Pharmacol; 1976 Feb; 3(1):201-4. PubMed ID: 973942
    [No Abstract]   [Full Text] [Related]  

  • 17. A comparison of some extra-renal effects of spironolactone and canrenone.
    Huston GJ; Al-Dujaili EA
    Br J Clin Pharmacol; 1979 Apr; 7(4):385-92. PubMed ID: 444357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria.
    Cheng SC; Suzuki K; Sadee W; Harding BW
    Endocrinology; 1976 Oct; 99(4):1097-106. PubMed ID: 976190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potassium prorenoate: a new steroidal aldosterone antagonist.
    Hofmann LM; Chinn LJ; Pedrera HA; Krupnick MI; Suleymanov OD
    J Pharmacol Exp Ther; 1975 Aug; 194(2):450-6. PubMed ID: 1151770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.
    Sadée W; Dagcioglu M; Schröder R
    J Pharmacol Exp Ther; 1973 Jun; 185(3):686-95. PubMed ID: 4712657
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.